Docetaxel - paediatric investigation plan

docetaxel

Key facts

• Invented name:
  • Taxotere
  • Taxotere
• Active Substance:
  docetaxel
• Therapeutic area:
  Oncology
• Decision number:
  P/22/2008
• PIP number:
  Docetaxel
• Pharmaceutical form(s):
  Concentrate and solvent for solution for infusion
• Condition(s) / indication(s):
  Nasopharyngeal carcinoma
• Route(s) of administration:
  Intravenous use
• Contact for public enquiries:

  Aventis Pharma SA

  E-mail: [e-mail]; Country: France; Phone: [phone]; Fax: [phone]

• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  16/05/2008

Decision

P/22/2008: European medicines agency decision of 16 May 2008 on the application for agreement of a Paediatric Investigation Plan for Docetaxel, Taxotere (EMEA-000029-PIP01-07) in accordance with Regulation (EC) No 1901/2...

AdoptedReference Number: EMEA/244977/2008